News & Updates

Show Multimedia Only
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases

CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases

09 Sep 2022 bySarah Cheung

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

09 Sep 2022
Shift work carries higher cardiometabolic multimorbidity risk in hypertension

Shift work carries higher cardiometabolic multimorbidity risk in hypertension

08 Sep 2022

Hypertensive patients who work shifts face an increased risk of developing more than two cardiometabolic diseases or cardiometabolic multimorbidity, according to a study.

08 Sep 2022